J9341Inj thiotepa (tepylute) 1 mg
Published CMS Medicare Part B payment-limit context for J9341, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$36.64
per 1 MG · Medicare Part B
Down 5.0%from $38.55 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$38.8174$36.3726
2024-Q4: Not published; 2025-Q1: Not published; 2025-Q2: Not published; 2025-Q3: Not published; 2025-Q4: Not published; 2026-Q1: $38.55; 2026-Q2: $38.55; 2026-Q3: $36.64
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Thiotepa ingredient family (FDA data as of August 20, 2026).
Tepylute
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Thiotepa presentations
1 other CMS codeSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J9342 | Inj thiotepa nos 1 mg | $4.931 per 1 MG | $5.738 per 1 MG | Down 14.1% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.